Document is current
Any future updates will be listed below
-
Authors
Hoshino, Junichi
Ohigashi, Tomohiro
Tsunoda, Ryoya
Ito, Yukiko
Kai, Hirayasu
Saito, Chie
Okada, Hirokazu
Narita, Ichiei
Wada, Takashi
Maruyama, Shoichi
Pisoni, Ronald
Pecoits-Filho, Roberto
Yamagata, Kunihiro
-
Funding
Funding for this research was provided by:
Japan Society for the Promotion of Science (24K14335)
Japan Agency for Medical Research and Development
Kyowa Kirin, Japan
Mitsubishi Tanabe Pharma Corporation
- License Information
-
More Information
Article History
Received: 1 July 2024
Accepted: 22 October 2024
First Online: 2 November 2024
Declarations
:
: The authors declare no competing interests. The REACH-J study is supported by Kyowa Kirin Co. Ltd. and Tanabe-Mitsubishi Pharm Ltd. Dr. Okada is funded by Takeda Pharm., Chugai Pharm., Kyowa-Hakko Kirin, Pfizer, Boehinger Ingelheim, Astellas Pharm., Otsuka Pharm., MSD, Shionogi, Novaltis, Sumitomo Dainippon Pharm., Mitsubishi Tanabe Pharm., and Daiichi Sankyo Co. Dr. Pecoits-Filho and Dr. Pisoni are members of Clinical Research for the non-profit organization Arbor Research Collaborative for health, which has designed and carried out the Dialysis Outcomes and Practice Pattern Study (DOPPS) Program. The DOPPS program is supported by Amgen, Kyowa Kirin, AbbVie Inc., Sanofi Renal, Baxter Healthcare, and Vifor Fresenius Medical Care Renal Pharma Ltd. Additional support for specific projects and countries is also provided in Canada by Amgen, BHC Medical, Janssen, Takeda, Kidney Foundation of Canada (for logistics support); in Germany by Hexal, DGfN, Shire, WiNe Institute; and for the Peritoneal-DOPPS in Japan by the Japanese Society for Peritoneal Dialysis (JSPD). The DOPPS.org website lists the full details. JDOPPS was administered by the Arbor Research Collaborative for Health, Ann Arbor, MI, USA, and supported by Kyowa Kirin Co. Ltd. All support is provided without restrictions on publications. All other authors have no conflict disclosure.
: The study’s protocol was approved by the Tsukuba institutional review board (IRB) (H27-199) and the review board of the Japanese Society of Nephrology (No. 29), and has been or will be approved by the IRB of each participating facility. The study procedures fully adhered to the Declaration of Helsinki and the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement, and was registered with the University Hospital Medical Information Network (UMIN000022145).
: Informed consent was and will be obtained from all individual participants included in the study.
